SCHEMBL29844055

SCHEMBL29844055

COC1(c2ccc(C(=O)N3CCC4(CC3)CCN(c3ccc(C(F)(F)F)cc3)CC4)cc2)COC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 9/20 0.53
▸ TSHR P16473 5/20 0.53
▸ CYP2D6 P10635 3/20 0.53
▸ CYP1A2 P05177 3/20 0.53
▸ HIF1A Q16665 3/20 0.53
▸ USP2 O75604 4/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ CYP2C9 P11712 3/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ MRGPRX4 Q96LA9 1/20 0.45
▸ HTT P42858 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ EPHX2 P34913 1/20 0.43
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577522 0.92 HTT (0.52) CYP3A4TSHRCYP1A2SMN1; SMN2ALDH1A1
SCHEMBL23577901 0.89 MEN1 (0.50) CYP3A4TSHRCYP2C9MRGPRX4MEN1
SCHEMBL23577535 0.88 MEN1 (0.49) CYP3A4TSHRSMN1; SMN2ALDH1A1CYP2C9
SCHEMBL24529922 0.88 MEN1 (0.53) TSHRCYP1A2SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL23578412 0.86 CYP3A4 (0.56) CYP3A4TSHRCYP2D6CYP1A2HIF1A
SCHEMBL23605611 0.85 CYP3A4 (0.51) CYP3A4TSHRCYP2D6CYP1A2HIF1A
SCHEMBL23605586 0.84 NAMPT (0.41) CYP3A4TSHRSMN1; SMN2ALDH1A1CYP2C9
SCHEMBL23577864 0.84 KMT2A (0.45) CYP3A4TSHRCYP2C9MRGPRX4MEN1
SCHEMBL23605567 0.83 HCRTR1 (0.40) TSHRALDH1A1MRGPRX4HTTMAPT
SCHEMBL23577498 0.82 TSHR (0.44) CYP3A4TSHRHIF1AUSP2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081509-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Zydus Lifesciences Limited (IN) 2022-11-02 — — EP claimed
CN-114901640-A Novel compounds useful for the treatment of dyslipidemia 兹杜斯生命科学有限公司 2022-08-12 — — CN claimed
US-20230089247-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA ZYDUS LIFESCIENCES LIMITED (IN) 2023-03-23 — — US disclosed
EP-4081509-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Zydus Lifesciences Limited (IN) 2022-11-02 — — EP disclosed
CN-114901640-A Novel compounds useful for the treatment of dyslipidemia 兹杜斯生命科学有限公司 2022-08-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089247-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA PCSK9, CETP, LCAT CYP3A4 605/4885TSHR 3435/4885CYP2D6 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback